BREAKING NEWS: FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer (read more here).
Go here to learn more or to get a mailed copy.
Home » Bio
FGFR Inhibition to Develop Effective Combination Therapies..
The University of Texas MD Anderson Cancer Center
Identification and integration of clinical features, genetic..
Paul Nguyen, MD:
Dana-Farber Cancer Institute, Harvard University
Anthony D’Amico, MD, PhD and Phillip Kantoff, MD
One of the causes for the initiation..
William G. Nelson, MD, PhD – :
Johns Hopkins MedicineInduction of Synthetic Lethality with Epigenetic therapy (ISLET) for Systemic Treatment of Prostate Cancer
Srinivasan Yegnasubramanian, MD, PhD; Jun O. Liu, PhD; Stephen B. Baylin, MD; Michael A. Carducci, MD; Martin J. Aryee, PhD
When Dr. Peter Nelson is on the..
View All Board Members here.
Chairman andChief Executive OfficerBanyan Biomarkers, Inc.
Targeting Therapy-Induced Resistance Mechanisms in the Prostate..
Fred Hutchinson Cancer Research Center